MedWatch

Novo Nordisk expands research collaboration to develop hemophilia drug

Collaborations between Novo Nordisk and US-based biotech firm 2Seventy Bio, spun off from Bluebird Bio, have expanded to include the development of a treatment for bleeding disorder hemophilia A.

Photo: Stine Tidsvilde

Under the banner of a joint research and development, Novo Nordisk and US-based biotech firm 2Seventy Bio will develop a drug candidate for genetic bleeding disorder hemophilia A, reports a press release from 2Seventy Bio.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs